According to Cleveland.com, Athersys, Inc has successfully completed treating its first clinical trial patient at the Cleveland Clinic. They're using stem cell therapy to determine the maximum dosage of Multistem, a medicine that is used after a heart attack.
B.J. Lehmann, president and chief operating officer, at Athersys, had this to say about the success:
"We are excited about the potential of MultiStem to provide benefit in multiple diseases and conditions, and we look forward to providing additional information about this Phase I clinical trial and other studies as we move our programs ahead."
Tuesday, October 14, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment